Jubilant Pharmova is currently trading at RS 1121.65, up by RS 25.95 or 2.37% from its previous close of RS 1095.70 on the BSE.

The stock opened at RS 1099.15 and touched an intraday high of RS 1134.00 and a low of RS 1093.00. So far, around 6005 shares have been traded on the counter.

The BSE ‘A’ group stock, with a face value of RS 1, has recorded a 52-week high of RS 1309.00 on November 7, 2024, and a 52-week low of RS 823.70 on April 9, 2025. During the past week, the scrip has traded between RS 1136.90 and RS 1081.00. The company’s current market capitalization stands at RS 17880.10 crore.

The promoters hold 47.68%, while institutional investors and non-institutional investors hold 26.92% and 25.40%, respectively.

In a key development, Jubilant Pharmova’s wholly owned subsidiary Jubilant HollisterStier LLC (JHS) has launched its third Sterile Fill & Finish line at its Spokane Manufacturing Facility in Washington, US. The facility has successfully produced its first commercial batch, marking the beginning of revenue generation from this new line.

This expansion adds 50% more capacity to JHS’s Spokane facility and forms a major part of its multi-phase growth strategy. With the commissioning of a fourth manufacturing line underway, JHS is on track to double its total sterile injectable production capacity in the US.

The investment strengthens JHS’s leadership in domestic pharmaceutical manufacturing and supports US national health security by reducing dependence on offshore supply chains.

Jubilant Pharmova (formerly Jubilant Life Sciences) operates in the fields of pharmaceuticals, contract research and development services, and proprietary novel drug discovery.